Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $39.00

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $39.00.

A number of equities analysts recently weighed in on ARTV shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Finally, HC Wainwright boosted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th.

Insiders Place Their Bets

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. bought 24,944 shares of the company’s stock in a transaction on Friday, July 31st. The shares were bought at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the transaction, the director owned 17,329,570 shares of the company’s stock, valued at approximately $172,082,630.10. This trade represents a 0.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders purchased 1,965,251 shares of company stock valued at $16,188,035. 1.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the third quarter valued at $41,000. State of Wyoming acquired a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth $45,000. Bank of America Corp DE increased its holdings in shares of Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $53,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $58,000.

Artiva Biotherapeutics Price Performance

ARTV opened at $11.09 on Monday. The business has a 50 day moving average price of $10.38 and a two-hundred day moving average price of $8.52. The company has a market cap of $542.19 million, a PE ratio of -3.36 and a beta of 2.16. Artiva Biotherapeutics has a 52 week low of $2.22 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). As a group, sell-side analysts expect that Artiva Biotherapeutics will post -2.62 EPS for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.